<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010903</url>
  </required_header>
  <id_info>
    <org_study_id>19_0077</org_study_id>
    <nct_id>NCT04010903</nct_id>
  </id_info>
  <brief_title>Investigation of Urinary Biomarkers for the Diagnosis of Insulin Resistance</brief_title>
  <acronym>BIOMUIR</acronym>
  <official_title>Investigation of Urinary Biomarkers for the Diagnosis of Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at the identification and the quantification of urinary branched-chain amino
      acids (BCAAs) by mass spectometry in healthy subjects and patients with insulin resistance
      and correlating urinary BCAAs with HOMA index.

      Blood and urine levels of BCAAs will be correlated with HOMA index to assess and quantify
      insulin resistance.

      Identification and quantification of urine BCAAs by an innovative method based on synthetic
      biology will also be performed.

      Correlations between mass spectometry and the innovative detection method of BCAAs will be
      searched.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood and urine samples will be collected in 330 persons to assess BCAAs levels and correlate
      them with HOMA index.

      Persons included will be:

      110 persons with BMI&gt;27 and HOMA &gt;4 with no diabetes 110 persons with BMI&gt;27 and HOMA &lt; 4
      with no diabetes 110 persons with BMI &lt; 27 and HOMA &lt;4 with no diabetes, including at least
      50 men and 50 women, 30 aged 18-35, 30 aged 36-55, 30 aged 56-75.

      Urine BCAAs will be measured by both mass spectrometry and the innovative method based on
      synthetic biology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort of subjects with/without overweight and with/without insulin resistance</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between urinary levels of BCAAs and HOMA index</measure>
    <time_frame>through study completion, an average of two years and a half</time_frame>
    <description>Identification of urinary BCAAs as markers of insulin resistance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between blood and urine BCAAs levels</measure>
    <time_frame>through study completion, an average of two years and a half</time_frame>
    <description>Validation of urinary BCAAs as biomarkers of insulin resistance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>HEALTHY SUBJECTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBJECTS WITH BMI&lt;27 and HOMA&lt;4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OVERWEIGHT NON INSULINRESISTANT PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBJECTS WITH BMI&gt;27 and HOMA&lt;4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OVERWEIGHT INSULINRESISTANT PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBJECTS WITH BMI&gt;27 and HOMA&gt;4</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>assessment of biomarkers of insulin resistance</intervention_name>
    <description>blood and urine sample collection for assays of BCAAs</description>
    <arm_group_label>HEALTHY SUBJECTS</arm_group_label>
    <arm_group_label>OVERWEIGHT INSULINRESISTANT PATIENTS</arm_group_label>
    <arm_group_label>OVERWEIGHT NON INSULINRESISTANT PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no diabetes

          -  according to studied subpopulations: BMI&lt;27 and HOMA &lt;4, BMI&gt;27 and HOMA&gt;4, BMI&gt;27 and
             HOMA&lt;4

        Exclusion Criteria:

          -  pregnancy or lactation

          -  active or suspected chronic infection

          -  treatment affecting insulin sensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIE BARDE</last_name>
    <role>Study Director</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ERIC RENARD, MD</last_name>
    <phone>+33 467 338 384</phone>
    <email>e-renard@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC RENARD, MD</last_name>
      <phone>+33467338384</phone>
      <email>e-renard@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INSULIN RESISTANCE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

